Connect to other sites within the UBM Medica Network
First-Line Nivolumab Could Be Good Option in Lung Cancer
Two parts of a phase I trial found that nivolumab could be a good first-line treatment option for patients with advanced non–small-cell lung cancer.
Diet, Social Restrictions Fail to Decrease Infections in Pediatric AML
Dietary, pet, and social contact restrictions did not have any effect on infectious complications in children undergoing intensive treatment of acute myeloid leukemia.
Ovarian Cancer Risk Factors Show Substantial Heterogeneity Across Histologic Subtypes
A large, prospective analysis showed that risk factors for ovarian cancer demonstrate substantial heterogeneity in their associations with histologic subtypes of the disease.
FGFR Inhibitor Dovitinib Shows Modest Efficacy in Squamous NSCLC
The FGFR inhibitor dovitinib showed modest efficacy in a phase II trial of patients with pretreated, advanced squamous cell lung cancer with FGFR1 amplification
Life Expectancy in CML Patients Approaching General Population’s
A study covering 4 decades of patients with chronic myeloid leukemia in Sweden found dramatic improvements in life expectancy since the advent of tyrosine kinase inhibitor therapy.
Three SNPs Associated With Overall Survival in Pediatric Ewing Sarcoma
Three single-nucleotide polymorphisms were identified that are significantly associated with OS in two separate cohorts of pediatric Ewing sarcoma patients.
Molecular-Based Classification for Endometrial Cancer Could Help Predict Survival
Researchers were able to molecularly classify endometrial cancers with distinct survival differences using a new classification tool called ProMisE that uses clinically applicable methods.
Ibrutinib Improves on Standard of Care in CLL/SLL
A trial found that ibrutinib in combination with bendamustine and rituximab is superior to standard of care in patients with previously treated CLL/SLL.
Adjuvant Chemo Ups Survival in High-Risk Localized Prostate Cancer
The addition of docetaxel and prednisone to standard therapy may be the first effective adjuvant chemotherapy treatment for high-risk prostate cancer patients.
Palbociclib, Fulvestrant Delays HR-Positive Breast Cancer Progression
The addition of palbociclib to fulvestrant delayed disease progression in women with HR-positive, HER2-negative metastatic breast cancer.
Anastrozole Trumps Tamoxifen in DCIS
Treatment of postmenopausal DCIS patients with the aromatase inhibitor anastrozole resulted in higher breast cancer–free survival rates compared with treatment with tamoxifen.
November 2015 News Roundup
In this November news roundup we highlight some of the top stories of the month, including several FDA approvals, new breast cancer guidelines, and more.
By clicking Accept, you agree to become a member of the UBM Medica Community.